Bispecific Antibody Production

Developing Bispecific Antibodies (BsAbs) presents unique challenges—from molecular instability to complex impurities during scale-up. At Mycenax, we bridge the gap between innovative design and high-yield GMP production. Explore our four-part technical series below to discover how we optimize every stage of the BsAb lifecycle to ensure your clinical and commercial success.

Bispecific Antibodies: Navigating From Design To Market Success

Each bispecific antibody design should be unique. The design of bispecific antibodies (BsAbs) should not be limited to only one format but rather should be determined based on their individual characteristics. Currently, there are over 100 different formats for BsAbs, aiming to address pairing errors and avoid patent infringement. In addition to these considerations, the design of BsAb formats requires a more comprehensive assessment. Factors influencing BsAb format design include half-life, mechanism of action (MoA), target characteristics, and considerations for issues arising during the manufacturing process such as yield, impurities, and conformational stability. A common challenge in BsAb development is low yield and poor stability. 

Read More →

Cell Line Development Screening: The First Crucial Step For Yield And Critical Quality Attributes

The selection of representative cell lines for expressing bispecific antibodies (BsAbs) is a crucial initial stage that significantly influences overall process yield and quality. The chosen cell lines represent the basic productivity and protein quality of the BsAb, impacting the potential for subsequent process development, scalability, stability, and purity of the main product. Because the structure of a BsAb is more complex than that of antibodies, it will also encounter more production problems in manufacturing, such as low product yield, erroneous chain assembly, and high aggregate levels. Therefore, the extensive screening and evaluation of multiple BsAb-expressing cell clones at this stage are necessary and play a pivotal role. Having a suitable clone can reduce the problems that upstream and downstream processes may face. Optimizing the expression plasmid and improving the screening strategies can help us obtain the best production clone. 

Read More →

Process Optimization: The Key To Enhancing Yield And Quality In Bispecific Antibody Production

Bispecific antibodies (BsAbs) pose inherent challenges in expression, often leading to issues such as aggregation, fragmentation, and the generation of diverse charge variants due to their complex structures. Consequently, optimizing the upstream process for BsAb production is imperative. This optimization involves meticulous steps aimed at refining the production process, ultimately enhancing both the yield and quality of the final product.

Read More →

The Downstream Process: Playing A Crucial Role In Extracting Essence

The goal of downstream process (DSP) development for bispecific antibodies (BsAbs) is to develop a method for obtaining highly purified bsAbs with optimal recovery and quality. Like traditional antibodies, the concept of the chromatography platform can be applied to DSP development. However, bsAb DSP development is more challenging due to the higher complexity of product-related impurities. The principle of the bsAb purification strategy was mainly based on the difference between the product and the impurities, as illustrated in Figure 1. In addition, some additives could be used to improve resolution during chromatography.

Read More →